Stockreport
Biologic Therapeutics Drugs Market Size Projections Exhibit a CAGR of 12.2%%, Likely to Attain a Value of USD 1485.0 Billion by 2033 [Yahoo! Finance]
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.amgen.com
North America emerged as the largest global biologic therapeutics drugs market region, with a 39.8% market revenue share in 2023. Newark, April 25, 2024 (GLOBE NEWSWIRE) -- The Brainy Insights estimates that the USD 469.7 billion biologic therapeutics drugs market will reach USD 1485.0 billion by 2033. Biologic therapeutics drugs are composed of proteins that have been genetically engineered using human DNA. They could be biological entities like tissues and cells or complex mixes of different substances like proteins, carbohydrates, and nucleic acids. Moreover, biologics therapeutics drugs originate from naturally occurring sources such as humans, animals, and microorganisms, from which various therapeutic products such as blood components, vaccines, and recombinant therapeutic proteins are produced. The frequency and diagnosis of chronic illnesses have increased the need for sophisticated diagnostics and treatment medications, driving the global biologics therapeutics drugs market
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | AMGN | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
AMGN alerts
AMGN alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
NEWS
NEWS
- Amgen's Q1 Earnings: Solid All Court Progress, Major Weight Loss Catalyst Pending [Seeking Alpha][Seeking Alpha]
- Amgen Inc. (NASDAQ: AMGN) had its price target raised by analysts at UBS Group AG from $284.00 to $307.00. They now have a "neutral" rating on the stock.[MarketBeat]
- Amgen Inc. (NASDAQ: AMGN) had its price target raised by analysts at Morgan Stanley from $271.00 to $310.00. They now have an "equal weight" rating on the stock.[MarketBeat]
- Amgen Inc. (NASDAQ: AMGN) had its price target lowered by analysts at Royal Bank of Canada from $332.00 to $328.00. They now have an "outperform" rating on the stock.[MarketBeat]
- Amgen (AMGN) Q1 Earnings Top, Stock Up on Obesity Drug Update [Yahoo! Finance][Yahoo! Finance]
- More
AMGN
SEC Filings
SEC Filings
- 5/3/24 - Form 4
- 5/3/24 - Form 4
- 5/3/24 - Form 4
- AMGN's page on the SEC website
- More